secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001213900-26-037524
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports early LYMPHIR launch momentum with 83% of target accounts in formulary review
--------------------------------------------------------------------------------

- 83% of target accounts have added or are actively progressing LYMPHIR through formulary review.
- ~135 health plans, covering ~80% of covered lives, secured; no reimbursement denials reported.
- Repeat orders from early accounts; initial penetration into community infusion centers underway.
- Investigator-sponsored studies: positive topline data in DLBCL at ASTCT 2026; Phase I combo with pembrolizumab completed.
- International expansion underway via distribution agreements in Europe and Middle East.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026037524/0001213900-26-037524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026037524/ea0284323-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-037524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer